Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex

Journal of Neuropathology and Experimental Neurology

Volumn 61, Issue 8, 2002, Pages 678-688

  Hoozemans, Jeroen J M ^a,b   Brückner, Martina K ^a,d   Rozemuller, Annemieke J M ^a,c   Veerhuis, Robert ^a,b   Eikelenboom, Piet ^a,b   Arendt, Thomas ^a,d  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alzheimer disease; Cell cycle; Cyclin D1; Cyclin E; Cyclo oxygenase; Neuron; Non steroidal anti inflammatory drugs

Indexed keywords

AMYLOID BETA PROTEIN; CYCLIN D1; CYCLIN E; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG TARGETING; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; TEMPORAL CORTEX;

EID: 0036323485     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/61.8.678     Document Type: Article

References (48)

1. Nonsteroidal anti-inflammatory drug use and breast cancer risk
2. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer
3. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
4. Aspirin use and reduced risk of fatal colon cancer
5. The role of cyclooxygenases in inflammation, cancer, and development
6. Mechanism of action of antiinflammatory drugs
7. Cyclooxygenase in biology and disease
8. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains
9. Distribution of cyclo-oxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs
10. Regional distribution of cyclo-oxygenase-2 in the hippocampal formation in Alzheimer's disease
11. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain
12. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain
13. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
14. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice
15. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice
16. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia
17. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage
18. Alzheimer's disease as a disorder of mechanisms under-lying structural brain self-organization
19. Neuronal apoptosis at the G1/S cell cycle checkpoint
20. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo
21. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells
22. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398
23. COX-2 expression and cell cycle progression in human fibroblasts
24. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism
25. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
26. Staging of Alzheimer's disease-related neurofibrillary changes
27. Neuropathological stageing of Alzheimer-related changes
28. Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy
29. Ectopic cell cycle proteins perdict the sites of neuronal cell death in Alzheimer's disease brain
30. Cell cycle markers in the hippocampus in Alzheimer's disease
31. Downregulation of neuronal cyclo-oxygenase-2 expression in end stage Alzheimer's disease
32. Oxidative damage is the earliest event in Alzheimer disease
33. Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration
34. Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease
35. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease
36. Interleukin-lbeta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: Involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB
37. Cyclin D1 is an essential mediator of apoptotic neuronal cell death
38. Intranuclear compartmentalization of cyclin E during the cell cycle: Disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer
39. Cell cycle-dependent localization of the CDK2-cyclin E complex in Cajal (coiled) bodies
40. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation
41. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients
42. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib
43. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
44. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1)
45. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells
46. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism
47. Interaction of cyclooxy-genases with an apoptosis- and autoimmunity-associated protein
48. Cyclo-oxygenase-2 inhibitors: Rationale and therapeutic potential for Alzheimer's disease